ロード中...

Acetylcholinesterase inhibitor treatment for myasthenia gravis

BACKGROUND: In myasthenia gravis, antibody‐mediated blockade of acetylcholine receptors at the neuromuscular junction abolishes the naturally occurring ‘safety factor’ of synaptic transmission. Acetylcholinesterase inhibitors provide temporary symptomatic treatment of muscle weakness but there is co...

詳細記述

保存先:
書誌詳細
出版年:Cochrane Database Syst Rev
主要な著者: Mehndiratta, Man Mohan, Pandey, Sanjay, Kuntzer, Thierry
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley & Sons, Ltd 2014
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7390275/
https://ncbi.nlm.nih.gov/pubmed/25310725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD006986.pub3
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!